Chemesis International Inc. Subsidiary, Natural Ventures PR, LLC, to Remain Operational During COVID-19 Pandemic
Chemesis International Inc. Announces Closing of CDN $5,000,000 Private Placement and Settlement of Debt
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer